Ying Lin
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation (NCT05761470) | Ying Lin | 2022-05-06 |
Track Ying Lin automatically
Every clearance here is in the API, with alerts when new ones post.